SCHEMBL1783240

SCHEMBL1783240

COc1cccc(-c2nsc(=O)o2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 7/20 0.63
NOTUM Q6P988 2/20 0.57
PSMB11 A5LHX3 1/20 0.56
PSMD11 O00231 1/20 0.56
PSMD12 O00232 1/20 0.56
PSMD14 O00487 1/20 0.56
PSMA7 O14818 1/20 0.56
PSMD3 O43242 1/20 0.56
PSMC3 P17980 1/20 0.56
PSMB1 P20618 1/20 0.56
PSMA1 P25786 1/20 0.56
PSMA2 P25787 1/20 0.56
PSMA3 P25788 1/20 0.56
PSMA4 P25789 1/20 0.56
PSMB9 P28065 1/20 0.56
PSMA5 P28066 1/20 0.56
PSMB4 P28070 1/20 0.56
PSMB6 P28072 1/20 0.56
PSMB5 P28074 1/20 0.56
PSMC2 P35998 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1781272 0.84 PSMB8 (0.56) PSMB8PSMB11PSMD11PSMD12PSMD14
SCHEMBL1425626 0.81 PSMB8 (0.62) PSMB8NOTUMPSMB11PSMD11PSMD12
SCHEMBL1781114 0.80 PSMB8 (0.69) PSMB8NOTUMPSMB11PSMD11PSMD12
SCHEMBL1504647 0.77 PSMB8 (0.61) PSMB8PSMB11PSMD11PSMD12PSMD14
SCHEMBL11393873 0.77 PSMB8 (0.53) PSMB8PSMB11PSMD11PSMD12PSMD14
SCHEMBL11396664 0.76 PSMB8 (0.69) PSMB8NOTUMPSMB11PSMD11PSMD12
SCHEMBL1780955 0.76 PSMB8 (0.69) PSMB8NOTUMPSMB11PSMD11PSMD12
SCHEMBL1181062 0.75 KDM4E (0.78) NOTUMKDM4EKMT2AALDH1A1HPGD
SCHEMBL1781069 0.75 PSMB8 (1.00) PSMB8NOTUMPSMB11PSMD11PSMD12
SCHEMBL28505575 0.74 NOTUM (0.58) NOTUMKDM4EKMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118274-A1 PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER CORNELL RESEARCH FOUNDATION, INC. (US) 2011-05-19 US claimed
WO-2013031694-A1 AMINE COMPOUND AND SALT THEREOF 富山化学工業株式会社 (JP) 2013-03-07 WO disclosed
US-20110118274-A1 PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER CORNELL RESEARCH FOUNDATION, INC. (US) 2011-05-19 US disclosed
WO-2009026579-A1 PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER CORNELL RESEARCH FOUNDATION, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118274-A1 PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER PSMB1, PSME1, PSMB2 PSMB8 22/4885NOTUM 3210/4885PSMB11 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.